Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Hematologic Oncology Update
CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management
The speakers explore the potential efficacy and side effect profiles of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. They discuss the optimal partner for combination therapy, address the issue of susceptibility to infection and response to vaccination, and emphasize the importance of educating patients and staff and implementing prophylaxis measures.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
